Vol. 5 No. 7 (2025)
Reimbursement Reviews

Naloxegol

decorative image of the issue cover

Published July 31, 2025

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses naloxegol, 12.5 mg and 25 mg, oral tablets.
  • Indication under consideration for reimbursement: Treatment of opioid-induced constipation in adult patients with an inadequate response to laxative(s), irrespective of the cause of pain (i.e., for both noncancer and cancer pain).